We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New One Minute Coronavirus Test Offers More than 90% Accuracy at Dramatically Lower Price

By LabMedica International staff writers
Posted on 14 May 2020
Print article
Image: The breath-test device developed by Professor Gabby Sarusi at Ben-Gurion University of the Negev (Photo courtesy of Professor Gabby Sarusi)
Image: The breath-test device developed by Professor Gabby Sarusi at Ben-Gurion University of the Negev (Photo courtesy of Professor Gabby Sarusi)
Israeli researchers have developed and are now validating a test that identifies carriers of the COVID-19 virus in less than a minute with greater than 90% accuracy and at a dramatically lower price than any other method available.

The test, developed by Ben-Gurion University of the Negev {(BGU) Beer-Sheva, Israel}, uses a chip with a dense array of metamaterial sensors that was designed specifically for this purpose. Particles from a simple breath test or throat and nose swabs, such as those already currently used for other tests, are placed on the chip. The system then analyzes the biological sample and provides an accurate positive/negative result within a minute via a cloud-connected system. The point-of-care device automatically backs up the results into a database that can be shared by authorities, making it easier than ever to track the course of the virus, as well as triage and treat patients.

The new method is based on the change in the resonance in the THz spectral range imposed by the coronavirus through a THz spectroscopy performed on the device. This spectral range has been employed in recent decades for the fast detection and identification of biological samples. Being electro-optical in nature, rather than biochemical, the test is not sensitive to environmental factors that can affect results of current testing methods.

Each test kit would cost between USD 50-100 to produce, which is far less than the current coronavirus test kits based on amplifying and identifying the viral RNA sequences, and therefore depend on costly reagents and biochemical reactions. Additionally, these PCR-based kits take hours, and in many cases days, to yield results and require logistically complicated shipping and handling of sensitive and infectious biological samples. In clinical trials, the test has demonstrated a better than 90% success rate as compared to Polymerase Chain Reaction (PCR) tests. Ongoing trials will now seek to determine if the test can identify the specific stage of COVID-19 infection as well as its presence.

"Right from the beginning of the trials, we received statistically significant results in line with our simulations and PCR tests," said Prof. Sarusi, deputy head for research at the School of Electrical and Computer Engineering and a faculty member of the Electro-Optical Engineering Unit at BGU. "We are continuing clinical trials and will compare samples from COVID-19 patients with samples from patients with other diseases to see if we can identify the different stages of the COVID-19 infection."

Related Links:
Ben-Gurion University of the Negev (BGU)

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more